Skip to main content
Top
Published in: Malaria Journal 1/2006

Open Access 01-12-2006 | Research

Limited polymorphism in Plasmodium falciparum ookinete surface antigen, von Willebrand factor A domain-related protein from clinical isolates

Authors: Jack S Richards, Nicholas J MacDonald, Damon P Eisen

Published in: Malaria Journal | Issue 1/2006

Login to get access

Abstract

Background

As malaria becomes increasingly drug resistant and more costly to treat, there is increasing urgency to develop effective vaccines. In comparison to other stages of the malaria lifecycle, sexual stage antigens are under less immune selection pressure and hence are likely to have limited antigenic diversity.

Methods

Clinical isolates from a wide range of geographical regions were collected. Direct sequencing of PCR products was then used to determine the extent of polymorphisms for the novel Plasmodium falciparum sexual stage antigen von Willebrand Factor A domain-related Protein (PfWARP). These isolates were also used to confirm the extent of diversity of sexual stage antigen Pfs28.

Results

PfWARP was shown to have non-synonymous substitutions at 3 positions and Pfs28 was confirmed to have a single non-synonymous substitution as previously described.

Conclusion

This study demonstrates the limited antigenic diversity of two prospective P. falciparum sexual stage antigens, PfWARP and Pfs28. This provides further encouragement for the proceeding with vaccine trials based on these antigens.
Appendix
Available only for authorised users
Literature
1.
go back to reference Moorthy VS, Good KF, Hill AVS: Malaria vaccine developments. Lancet. 2004, 363: 150-156. 10.1016/S0140-6736(03)15267-1.CrossRefPubMed Moorthy VS, Good KF, Hill AVS: Malaria vaccine developments. Lancet. 2004, 363: 150-156. 10.1016/S0140-6736(03)15267-1.CrossRefPubMed
2.
go back to reference Carter R: Spatial simulation of malaria transmission and its control by malaria transmission blocking vaccination. Int J Parasitol. 2002, 32: 1617-1624. 10.1016/S0020-7519(02)00190-X.CrossRefPubMed Carter R: Spatial simulation of malaria transmission and its control by malaria transmission blocking vaccination. Int J Parasitol. 2002, 32: 1617-1624. 10.1016/S0020-7519(02)00190-X.CrossRefPubMed
3.
go back to reference Williamson KC: Pfs230: from malaria transmission-blocking vaccine candidate toward function. Parasite Immunol. 2003, 25: 351-359. 10.1046/j.1365-3024.2003.00643.x.CrossRefPubMed Williamson KC: Pfs230: from malaria transmission-blocking vaccine candidate toward function. Parasite Immunol. 2003, 25: 351-359. 10.1046/j.1365-3024.2003.00643.x.CrossRefPubMed
4.
go back to reference Carter R: Transmission blocking malaria vaccines. Vaccine. 2001, 19: 2309-2314. 10.1016/S0264-410X(00)00521-1.CrossRefPubMed Carter R: Transmission blocking malaria vaccines. Vaccine. 2001, 19: 2309-2314. 10.1016/S0264-410X(00)00521-1.CrossRefPubMed
5.
go back to reference Yuda M, Yano K, Tsuboi T, Torii M, Chinzei Y: von Willebrand Factor A Domain-related Protein, a novel microneme protein of the malaria ookinete highly conserved throughout Plasmodium parasites. Mol Biochem Parasitol. 2001, 116: 65-72. 10.1016/S0166-6851(01)00304-8.CrossRefPubMed Yuda M, Yano K, Tsuboi T, Torii M, Chinzei Y: von Willebrand Factor A Domain-related Protein, a novel microneme protein of the malaria ookinete highly conserved throughout Plasmodium parasites. Mol Biochem Parasitol. 2001, 116: 65-72. 10.1016/S0166-6851(01)00304-8.CrossRefPubMed
6.
go back to reference Li F, Templeton TJ, Popov V, Comer JE, Tsuboi T, Torii M, Vinetz JM: Plasmodium ookinete-secreted proteins secreted through a common micronemal pathway are targets of blocking malaria transmission. J Biol Chem. 2004, 279: 26635-26644. 10.1074/jbc.M401385200.CrossRefPubMed Li F, Templeton TJ, Popov V, Comer JE, Tsuboi T, Torii M, Vinetz JM: Plasmodium ookinete-secreted proteins secreted through a common micronemal pathway are targets of blocking malaria transmission. J Biol Chem. 2004, 279: 26635-26644. 10.1074/jbc.M401385200.CrossRefPubMed
7.
go back to reference Abraham EG, Islam S, Srinivasan P, Ghosh AK, Valenzuela JG, Ribeiro JM, Kafatos FC, Dimopoulos G, Jacobs-Lorena M: Analysis of the Plasmodium and Anopheles transcriptional repertoire during ookinete development and midgut invasion. J Biol Chem. 2004, 279: 5573-5580. 10.1074/jbc.M307582200.CrossRefPubMed Abraham EG, Islam S, Srinivasan P, Ghosh AK, Valenzuela JG, Ribeiro JM, Kafatos FC, Dimopoulos G, Jacobs-Lorena M: Analysis of the Plasmodium and Anopheles transcriptional repertoire during ookinete development and midgut invasion. J Biol Chem. 2004, 279: 5573-5580. 10.1074/jbc.M307582200.CrossRefPubMed
8.
go back to reference Whittaker CA, Hynes RO: Distribution and evolution of von Willebrand/integrin A domains: widely dispersed domains with roles in cell adhesion and elsewhere. Mol Biol Cell. 2002, 13: 3369-3387. 10.1091/mbc.E02-05-0259.PubMedCentralCrossRefPubMed Whittaker CA, Hynes RO: Distribution and evolution of von Willebrand/integrin A domains: widely dispersed domains with roles in cell adhesion and elsewhere. Mol Biol Cell. 2002, 13: 3369-3387. 10.1091/mbc.E02-05-0259.PubMedCentralCrossRefPubMed
9.
go back to reference Gozar MM, Price VL, Kaslow DC: Saccharomyces cerevisiae-secreted fusion proteins Pfs25 and Pfs28 elicit potent Plasmodium falciparum transmission-blocking antibodies in mice. Infect Immun. 1998, 66: 59-64.PubMedCentralPubMed Gozar MM, Price VL, Kaslow DC: Saccharomyces cerevisiae-secreted fusion proteins Pfs25 and Pfs28 elicit potent Plasmodium falciparum transmission-blocking antibodies in mice. Infect Immun. 1998, 66: 59-64.PubMedCentralPubMed
10.
go back to reference Kaslow DC, Quakyi IA, Syin C, Raum MG, Keister DB, Coligan JE, McCutchan TF, Miller LH: A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature. 1988, 333: 74-76. 10.1038/333074a0.CrossRefPubMed Kaslow DC, Quakyi IA, Syin C, Raum MG, Keister DB, Coligan JE, McCutchan TF, Miller LH: A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature. 1988, 333: 74-76. 10.1038/333074a0.CrossRefPubMed
11.
go back to reference Duffy PE, Kaslow DC: A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as falciparum malaria transmission-blocking vaccines. Infect Immun. 1997, 65: 1109-1113.PubMedCentralPubMed Duffy PE, Kaslow DC: A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as falciparum malaria transmission-blocking vaccines. Infect Immun. 1997, 65: 1109-1113.PubMedCentralPubMed
12.
go back to reference Hafalla JC, Santiago ML, Pasay MC, Ramirez BL, Gozar MM, Saul A, Kaslow DC: Minimal variation in the Pfs28 ookinete antigen from Philippine field isolates of Plasmodium falciparum. Mol Biochem Parasitol. 1997, 87: 97-99. 10.1016/S0166-6851(97)00042-X.CrossRefPubMed Hafalla JC, Santiago ML, Pasay MC, Ramirez BL, Gozar MM, Saul A, Kaslow DC: Minimal variation in the Pfs28 ookinete antigen from Philippine field isolates of Plasmodium falciparum. Mol Biochem Parasitol. 1997, 87: 97-99. 10.1016/S0166-6851(97)00042-X.CrossRefPubMed
13.
go back to reference Eisen D, Billman-Jacobe H, Marshall VF, Fryauff D, Coppel RL: Temporal variation of the merozoite surface protein-2 gene of Plasmodium falciparum. Infect Immun. 1998, 66: 239-246.PubMedCentralPubMed Eisen D, Billman-Jacobe H, Marshall VF, Fryauff D, Coppel RL: Temporal variation of the merozoite surface protein-2 gene of Plasmodium falciparum. Infect Immun. 1998, 66: 239-246.PubMedCentralPubMed
14.
go back to reference Kaslow DC, Quakyi IA, Keister DB: Minimal variation in a vaccine candidate from the sexual stage of Plasmodium falciparum. Mol Biochem Parasitol. 1989, 32: 101-104. 10.1016/0166-6851(89)90134-5.CrossRefPubMed Kaslow DC, Quakyi IA, Keister DB: Minimal variation in a vaccine candidate from the sexual stage of Plasmodium falciparum. Mol Biochem Parasitol. 1989, 32: 101-104. 10.1016/0166-6851(89)90134-5.CrossRefPubMed
15.
go back to reference Tsuboi T, Kaslow DC, Gozar MM, Tachibana M, Cao YM, Torii M: Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates. Mol Med. 1998, 4: 772-782.PubMedCentralPubMed Tsuboi T, Kaslow DC, Gozar MM, Tachibana M, Cao YM, Torii M: Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates. Mol Med. 1998, 4: 772-782.PubMedCentralPubMed
16.
go back to reference Ya-Ping S, Alpers MP, Povoa MM, Lal AA: Single amino acid variation in the ookinete vaccine antigen from field isolates of Plasmodium falciparum. Mol Biochem Parasitol. 1992, 50: 179-180. 10.1016/0166-6851(92)90254-H.CrossRef Ya-Ping S, Alpers MP, Povoa MM, Lal AA: Single amino acid variation in the ookinete vaccine antigen from field isolates of Plasmodium falciparum. Mol Biochem Parasitol. 1992, 50: 179-180. 10.1016/0166-6851(92)90254-H.CrossRef
17.
go back to reference Eisen DP, Saul A, Fryauff DJ, Reeder JC, Coppel RL: Alterations in Plasmodium falciparum genotypes during sequential infections suggest the presence of strain specific immunity. Am J Trop Med Hyg. 2002, 67: 8-16.PubMed Eisen DP, Saul A, Fryauff DJ, Reeder JC, Coppel RL: Alterations in Plasmodium falciparum genotypes during sequential infections suggest the presence of strain specific immunity. Am J Trop Med Hyg. 2002, 67: 8-16.PubMed
18.
go back to reference Hisaeda H, Collins WE, Saul A, Stowers AW: Antibodies to Plasmodium vivax transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 do not show synergism. Vaccine. 2001, 20: 763-770. 10.1016/S0264-410X(01)00402-9.CrossRefPubMed Hisaeda H, Collins WE, Saul A, Stowers AW: Antibodies to Plasmodium vivax transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 do not show synergism. Vaccine. 2001, 20: 763-770. 10.1016/S0264-410X(01)00402-9.CrossRefPubMed
20.
go back to reference Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J, Wu Y, Miura K, Long CA, Lambert L, Miles AP, Wang J, Stowers A, Miller LH, Saul A: Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine. 2005, 23: 3131-3138. 10.1016/j.vaccine.2004.12.019.CrossRefPubMed Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J, Wu Y, Miura K, Long CA, Lambert L, Miles AP, Wang J, Stowers A, Miller LH, Saul A: Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine. 2005, 23: 3131-3138. 10.1016/j.vaccine.2004.12.019.CrossRefPubMed
Metadata
Title
Limited polymorphism in Plasmodium falciparum ookinete surface antigen, von Willebrand factor A domain-related protein from clinical isolates
Authors
Jack S Richards
Nicholas J MacDonald
Damon P Eisen
Publication date
01-12-2006
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2006
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/1475-2875-5-55

Other articles of this Issue 1/2006

Malaria Journal 1/2006 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.